Point72 Asia Singapore Pte. Ltd. Purchases New Holdings in Moderna, Inc. (NASDAQ:MRNA)

Point72 Asia Singapore Pte. Ltd. acquired a new position in Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 22,506 shares of the company’s stock, valued at approximately $936,000.

Other large investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB lifted its holdings in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after buying an additional 587 shares during the period. Compass Planning Associates Inc acquired a new position in shares of Moderna during the 4th quarter worth about $37,000. Venturi Wealth Management LLC increased its stake in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after acquiring an additional 664 shares during the last quarter. Crowley Wealth Management Inc. acquired a new stake in Moderna in the fourth quarter worth $41,000. Finally, Itau Unibanco Holding S.A. raised its stake in Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock worth $42,000 after buying an additional 343 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance

Shares of Moderna stock opened at $24.02 on Thursday. The stock’s 50-day moving average is $28.52 and its 200 day moving average is $36.08. Moderna, Inc. has a one year low of $23.15 and a one year high of $170.47. The firm has a market cap of $9.29 billion, a price-to-earnings ratio of -2.59 and a beta of 1.99.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The company had revenue of $108.00 million for the quarter, compared to analysts’ expectations of $130.35 million. During the same quarter in the prior year, the firm earned ($3.07) EPS. The business’s revenue was down 35.3% on a year-over-year basis. On average, sell-side analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on MRNA shares. Morgan Stanley dropped their target price on shares of Moderna from $39.00 to $32.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 9th. Barclays dropped their price objective on Moderna from $45.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Friday, May 2nd. The Goldman Sachs Group downgraded shares of Moderna from a “buy” rating to a “neutral” rating and cut their target price for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Royal Bank of Canada decreased their price objective on shares of Moderna from $32.00 to $28.00 and set a “sector perform” rating on the stock in a report on Friday, May 2nd. Finally, Bank of America dropped their price target on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a report on Tuesday, February 11th. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Moderna currently has an average rating of “Hold” and an average price target of $53.95.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.